NURO News and Press, NeuroMetrix Inc. From 03/21/23

WOBURN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39 th Annual Meeting on March 23 - 26 in Ft. Lauderdale, FL. In addition, two scientific posters reporting new data on the use of Quell i...

NeuroMetrix, Inc. (NURO) Q4 2022 Results Conference Call February 23, 2023 8:00 AM ET Company Participants Thomas Higgins - Senior VP, CFO & Treasurer Shai Gozani - Founder, Chairman, CEO, President & Secretary Conference Call Participants Jarrod Cohen ...

NeuroMetrix press release ( NASDAQ: NURO ): Q4 GAAP EPS of -$0.09. Revenue of $1.84M (+1.1% Y/Y). Gross profit in Q4 2022 was $1.2 million, a decrease of 1.0% from the fourth quarter of 2021. The Q4 gross margin rate was 66.6% in comparison with 68.3% in the prior year. Higher...

WOBURN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2022. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and o...

WOBURN, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 fourth quarter and year end financial results before the opening of the market on February 23, 2023. The Company will host a conference call at 8:00 a.m., Eastern Time...

WOBURN, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the commercial availability of DPNCheck 2.0, the Company's latest point-of-care device that leverages gold-standard nerve conduction technology to detect peripheral neuropathy. DPNCheck 2.0 provides ...

WOBURN, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will introduce Quell Fibromyalgia at the American College of Rheumatology Annual Meeting, ACR Convergence 2022, on November 12 – 14 in Philadelphia, Pennsylvania. Quell Fibromyalgia is a wearable neurom...

WOBURN, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) --  NeuroMetrix, Inc. (Nasdaq: NURO) today announced the strategic launch of its Quell ® Fibromyalgia device through the Pathfinder Program. Quell Fibromyalgia is the first and only medical device authorized by the U.S. Food and Dr...

NeuroMetrix, Inc. (NURO) Q3 2022 Earnings Conference Call October 20, 2022, 8:00 am ET Company Participants Thomas Higgins - SVP & CFO Shai Gozani - CEO Conference Call Participants Jarrod Cohen - JM Cohen & Company William Church - TGRA Capit...

WOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and nine-month period ended September 30, 2022. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on in...